Blog

Amicus to delay filing for U.S. marketing rights for lead drug

Amicus Therapeutics Inc said it was unlikely to submit a U.S. marketing application for its lead drug, to treat Fabry disease, by the end of 2015 as expected, after U.S. health regulators asked for a more comprehensive analysis of trial data. Amicus’s stock slumped as much as 59 percent to $5.69, at which point about $956 million had been wiped off the biotechnology company’s market capitalization on Friday. The company

10 Best Specialty Dining Options on Cruises

Dinner on a cruise has traditionally meant set dining hours and big banquet tables, but that experience isn’t ideal for every traveler. Fortunately, cruise lines are increasingly offering specialty dining options that bring a new standard of excellence to the seas. Though not included covered by the all-inclusive rate, these restaurants offer high-end, intimate dining experiences at reasonable prices. In addition, more and more ships now feature menus that have

Weak jobs report leaves Federal Reserve tied to global growth

The weak U.S. September jobs report published Friday is another sign that Federal Reserve policy may be uncomfortably tethered to the strength of the global economy, as a year long swoon in exports helped wipe out manufacturing jobs and slow employment growth. As it tries to engineer the first U.S. interest rate increase in nearly a decade, the Fed wants economic growth to stay even marginally above what is viewed